Table 2. List of senomorphics and their targets.

SASP inhibitor	Target/function*	References
SB 203580	p38 MAPK** inhibitor	([60] Reviewed by [12])
UR-135756, BIRB 796	p38 MAPK inhibitor	[61]
Resveratrol	NF-ƙB inhibitor (IĸB-kinase inhibitor), AMPK and SIRT1 activator, others	[62–64]
Apigenin, Wogonin, Kaempferol	NF-ƙB inhibitors (IĸB-zeta)	[65]
Metformin	Inhibition of IKK/NF-ƙB, mitochondrial electron tranport, mitochondrial GPDH, and KDM6A/UTX, AMPK activator, others	[66–70]
Cortisol/corticosterone	IL-1α/NF-ƙB pathway inhibitors	[71]
NDGA	ROS (free radical scavenger)	[72]
Rapamycin	mTOR inhibitor, membrane-bound IL-1A translation inhibition, prelamin A, 53BP1	[73] [74] [110]
Ruxolitinib	Inhibition of JAK1/2 and ROCK	[75, 76]

*For many of the SASP inhibitors listed there have been described several targets.

**53BP1; p53 binding protein 1. AMPK; AMP-activated protein kinase. IKK; IĸB kinase. JAK; Janus kinase. KDM6A/UTX; lysine demethylase 6A. MAPK; mitogen-activated protein kinase. mTOR; mammalian target of rapamycin. NDGA; nordihydroguaiaretic acid. NF-ƙB; nuclear factor kappa light chain enhancer of activated B cells. ROS; reactive oxygen species.